Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PTGIR | P43119 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304807 | 0.83 | SIGMAR1 (0.54) | SIGMAR1SMN1; SMN2PTGIRDRD4HRH2 | |
| SCHEMBL12488080 | 0.83 | PAX8 (0.56) | SIGMAR1SMN1; SMN2PTGIRDRD4HRH2 | |
| SCHEMBL12488076 | 0.83 | PAX8 (0.56) | SIGMAR1SMN1; SMN2PTGIRDRD4HRH2 | |
| SCHEMBL12488083 | 0.83 | PAX8 (0.56) | SIGMAR1SMN1; SMN2PTGIRDRD4HRH2 | |
| SCHEMBL12489466 | 0.83 | PAX8 (0.56) | SIGMAR1SMN1; SMN2PTGIRDRD4HRH2 | |
| SCHEMBL15329360 | 0.82 | HRH2 (0.56) | SIGMAR1SMN1; SMN2PTGIRDRD4HRH2 | |
| SCHEMBL16081738 | 0.81 | S1PR1 (0.51) | SMN1; SMN2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL19502864 | 0.80 | SIRT2 (0.51) | SIGMAR1SMN1; SMN2DRD4KDM4E | |
| SCHEMBL13547217 | 0.80 | SIGMAR1 (0.63) | SIGMAR1SMN1; SMN2PTGIRDRD4HRH2 | |
| SCHEMBL8068944 | 0.80 | SIGMAR1 (0.62) | SIGMAR1SMN1; SMN2DRD4HRH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | claimed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | claimed |
| US-20180009787-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-11 | — | — | US | claimed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | claimed |
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| US-10023558-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-07-17 | — | — | US | disclosed |
| US-20180009787-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-11 | — | — | US | disclosed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023558-B2 | Compounds | SERPINB1, ELANE, MPO | SIGMAR1 3139/4885SMN1; SMN2 725/4885PTGIR 1200/4885 |
| US-20180009787-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | SIGMAR1 2706/4885SMN1; SMN2 879/4885PTGIR 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.